Alloy Therapeutics partners with Wheeler Bio to offer high-quality CMC development services and GMP manufacturing to partners in Alloy's bio tech ecosystem.
Alloy Therapeutics outlines its roadmap for advancing drug discovery technologies and services across modalities like antibodies, TCRs, bispecifics, and genetic medicines.
Alloy Therapeutics closed $42 million in Series D financing to advance its discovery technology and services to accelerate development across biologic modalities.
Alloy Therapeutics expands its antibody discovery services with two new senior vice presidents, John Lippincott and Kent Bondensgard, on the executive team.
Alloy’s Martin Leach is promoted to COO and Michael Schmidt joins as CSO to expand the company’s operational excellence and discovery services capacity.
Alloy Therapeutics democratizes access to antibody discovery and biologics discovery technology to enable and advance drug discovery in antibodies and TCRs.
Alloy Therapeutics licenses its ATX-Gx platform, enabling partners to accelerate fully human antibody discovery with advanced transgenic mouse models.